ESMO 2022 | Nivolumab and ipilimumab in advanced Merkel cell carcinoma

Sungjune Kim, MD, PhD, Moffitt Cancer Center, Tampa, FL, provides an overview of a Phase II trial (NCT03071406) of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with advanced Merkel cell carcinoma. 50 patients were stratified based on prior treatment with immunotherapy, with the primary objective being overall response rate (ORR). All patients who were treatment-naïve achieved a partial or complete response, whereas approximately a third of pretreated patients achieved a partial or complete response. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.